Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorDerwand, R.-
Autor(es): dc.creatorScholz, M.-
Data de aceite: dc.date.accessioned2026-02-09T12:36:49Z-
Data de disponibilização: dc.date.available2026-02-09T12:36:49Z-
Data de envio: dc.date.issued2020-06-30-
Data de envio: dc.date.issued2020-06-30-
Data de envio: dc.date.issued2020-09-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41625-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0306987720306435-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1164819-
Descrição: dc.descriptionCurrently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceMedical Hypotheses-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectTherapy-
Palavras-chave: dc.subjectChloroquine-
Palavras-chave: dc.subjectHydroxychloroquine-
Palavras-chave: dc.subjectZinc-
Título: dc.titleDoes zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.